Navigation Links
TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease
Date:12/9/2009

WALTHAM, Mass., Dec. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease. Three times as many newly diagnosed second-line patients received a TNF-alpha inhibitor versus one year ago (15.2 percent versus 5.6 percent). This boost is due in part to physicians' increased prescribing of Centocor Ortho Biotech's Remicade as a second- or third-line therapy for newly diagnosed patients.

"Our analysis of patient-level claims data shows that both Remicade and Abbott's Humira contributed to the increased uptake of TNF-alpha inhibitors in newly diagnosed patients. However, Remicade outpaces Humira substantially in second- and third-line treatment for these patients," stated Madhuri Borde, Ph.D., product director at Decision Resources. "While enthusiasm for agents with self-administration (e.g., Humira, UCB's Cimzia) may lead to slower growth for Remicade in the future, our survey results make it clear that physicians prescribe Remicade based on its perceived superior efficacy in inducing remission and in healing fistulizing forms of Crohn's disease compared with Humira and Cimzia."

The new Treatment Algorithms in Crohn's Disease report also finds that a major shift in U.S. gastroenterologists' prescribing patterns will occur over the next two years. More than 60 percent of U.S. surveyed gastroenterologists will increase their use of a top-down approach to treating Crohn's disease in newly diagnosed patients (i.e. starting with a biologic) and more than 70 percent will decrease their use of corticosteroids in newly diagnosed patients.

By combining patient-level claims data with physician survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models. Patient-level claims data finds that newly diagnosed patients receiving Remicade first- or second-line did not switch to Humira within their first year of treatment and a small percentage of newly diagnosed patients receiving Humira in these two lines switched to Remicade. These findings indicate that patients treated with either drug rarely switch to another biologic during their first year of treatment.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



For more information, contact:

Gisselle Morales                             Elizabeth Marshall
Decision Resources                           Decision Resources, Inc.
781-296-2691                                 781-296-2563
gmorales@dresources.com                      emarshall@dresources.com


SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
5. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
6. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
7. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
8. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
(Date:6/24/2016)... ... 24, 2016 , ... To succeed under value-based payments, healthcare ... unsure how to move forward, given the need to sustain current operations. PYA ... to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers ...
Breaking Medicine News(10 mins):